The drug was first approved in March 2006 in Europe to treat early stages of the illness in March 2006 and is available in Germany, Austria, Switzerland, Britain, Ireland, Denmark, Norway, Sweden, Greece and Spain.
The company, which is set to become part of Belgium's UCB SA in a Ђ4.4 billion (US$5.7 billion) deal, has said that sales of the drug could reach as much as Ђ350 million annually, reports AP.
Shares of Schwarz Pharma were up more than half a percent to Ђ106.13 in Frankfurt trading.
"We should use shock therapy to sober up the Americans. In this case, the Americans will speak about the need to resume dialogue. There is no other option"
The United States is concerned about the current crisis in the relations with Russia and suggests returning to reasonable policies to avoid a nuclear war